Mp68-15 Cardiovascular Outcomes of Patients With Advanced Prostate Cancer Treated With Leuprolide or Relugolix

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II (MP68)1 May 2024MP68-15 CARDIOVASCULAR OUTCOMES OF PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH LEUPROLIDE OR RELUGOLIX Austin Y. Ho, Parth Shah, Eric Li, Richard Bennett, Jonathan Aguiar, Clarissa Wong, Chalairat Suk-ouichai, Sai Kumar, Clayton Neill, Zequn Sun, Hiten Patel, Edward Schaeffer, Sean Sachdev, and Ashley Ross Austin Y. HoAustin Y. Ho , Parth ShahParth Shah , Eric LiEric Li , Richard BennettRichard Bennett , Jonathan AguiarJonathan Aguiar , Clarissa WongClarissa Wong , Chalairat Suk-ouichaiChalairat Suk-ouichai , Sai KumarSai Kumar , Clayton NeillClayton Neill , Zequn SunZequn Sun , Hiten PatelHiten Patel , Edward SchaefferEdward Schaeffer , Sean SachdevSean Sachdev , and Ashley RossAshley Ross View All Author Informationhttps://doi.org/10.1097/01.JU.0001008744.60568.e8.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Leuprolide is an injected GnRH agonist that has been the standard of care for patients receiving androgen deprivation therapy (ADT) for advanced prostate cancer. In December of 2020, relugolix was approved as the first oral GnRH antagonist which provided patients with an alternative form of ADT. Results of the phase III HERO study associated relugolix use with faster recovery of testosterone and potentially fewer major adverse cardiovascular events (MACE). In this study, we sought to determine the cardiovascular outcomes of patients with prostate cancer treated with leuprolide or relugolix at our multi-centered academic institution. METHODS: The Northwestern Electronic Data Warehouse was queried for men with an established diagnosis of prostate cancer who were prescribed leuprolide or relugolix from Jan 2018 - Sep 2023. Patients who were prescribed leuprolide were further stratified into a pre-relugolix era (Jan 2018-Nov 2020) and a post-relugolix era (Dec 2020-Sep 2023). Patients who received both medications were excluded. MACEs were defined as non-fatal myocardial infarction (MI), non-fatal stroke, or death from cardiovascular associated causes. A multivariable logistic regression model evaluated predictors of MACE. RESULTS: 2,509 men were prescribed leuprolide (n=1,195 in the pre-relugolix era, n=1,314 in the post-relugolix era) and 286 men were prescribed relugolix at our institution during the study period. The incidence of treatment emergent MACE was 7.9%, 4.3%, and 4.2% for the pre-relugolix leuprolide, post-relugolix leuprolide, and relugolix cohorts respectively. Results of the multivariable logistic regression are shown in Table 1. High CCI, Asian race, and a previous history of heart attack of stroke were associated with a significant increase in risk of MACE after initiating ADT. CONCLUSIONS: Our results demonstrated a previous history of MACE was the most significant variable associated with increased risk of MACE after initiating ADT (OR=9.29, p<0.001). While relugolix usage was not associated with decreased risk of MACE, it should be noted that patients prescribed relugolix tended to be younger, have fewer cardiac comorbidities, and have shorter terms of ADT compared to men prescribed leuprolide. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1114 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Austin Y. Ho More articles by this author Parth Shah More articles by this author Eric Li More articles by this author Richard Bennett More articles by this author Jonathan Aguiar More articles by this author Clarissa Wong More articles by this author Chalairat Suk-ouichai More articles by this author Sai Kumar More articles by this author Clayton Neill More articles by this author Zequn Sun More articles by this author Hiten Patel More articles by this author Edward Schaeffer More articles by this author Sean Sachdev More articles by this author Ashley Ross More articles by this author Expand All Advertisement PDF downloadLoading ...